Campuzano V, Montermini L, Lutz Y, Cova L, Hindelang C, Jiralerspong S, Trottier Y, Kish SJ, Faucheux B, Trouillas P, et al. Frataxin is reduced in Friedreich Ataxia patients and is Associated with mitochondrial membranes. Hum Mol Genet. 1997;6:1771–80. https://doi.org/10.1093/hmg/6.11.1771.
Article CAS PubMed Google Scholar
Clark E, Johnson J, Dong YN, Mercado-Ayon E, Warren N, Zhai M, McMillan E, Salovin A, Lin H, Lynch DR. Role of Frataxin Protein Deficiency and metabolic dysfunction in Friedreich Ataxia, an autosomal recessive mitochondrial disease. Neuronal Signal. 2018;2:NS20180060. https://doi.org/10.1042/NS20180060.
Article CAS PubMed PubMed Central Google Scholar
Koeppen AH. Friedreich’s Ataxia: Pathology, Pathogenesis, and Molecular Genetics. J Neurol Sci. 2011;303:1–12. https://doi.org/10.1016/j.jns.2011.01.010.
Article CAS PubMed PubMed Central Google Scholar
Condò I, Ventura N, Malisan F, Tomassini B, Testi R. A Pool of Extramitochondrial Frataxin that promotes cell survival. J Biol Chem. 2006;281:16750–6. https://doi.org/10.1074/jbc.M511960200.
Article CAS PubMed Google Scholar
Guccini I, Serio D, Condò I, Rufini A, Tomassini B, Mangiola A, Maira G, Anile C, Fina D, Pallone F, et al. Frataxin participates to the Hypoxia-Induced response in tumors. Cell Death Dis. 2011;2:e123. https://doi.org/10.1038/cddis.2011.5.
Article CAS PubMed PubMed Central Google Scholar
Schiavi A, Torgovnick A, Kell A, Megalou E, Castelein N, Guccini I, Marzocchella L, Gelino S, Hansen M, Malisan F, et al. Autophagy induction extends Lifespan and reduces lipid content in response to Frataxin Silencing in C. Elegans. Exp Gerontol. 2013;48:191–201. https://doi.org/10.1016/j.exger.2012.12.002.
Article CAS PubMed PubMed Central Google Scholar
Santos R, Lefevre S, Sliwa D, Seguin A, Camadro J-M, Lesuisse E. Friedreich Ataxia: Molecular mechanisms, Redox Considerations, and Therapeutic opportunities. Antioxid Redox Signal. 2010;13:651–90. https://doi.org/10.1089/ars.2009.3015.
Article CAS PubMed PubMed Central Google Scholar
Hou J-GG, Jankovic J. Movement disorders in Friedreich’s Ataxia. J Neurol Sci. 2003;206:59–64. https://doi.org/10.1016/s0022-510x(02)00321-0.
Payne RM, Wagner GR. Cardiomyopathy in Friedreich Ataxia: clinical findings and research. J Child Neurol. 2012;27:1179–86. https://doi.org/10.1177/0883073812448535.
Article PubMed PubMed Central Google Scholar
Cnop M, Mulder H, Igoillo-Esteve M. Diabetes in Friedreich Ataxia. J Neurochem. 2013;126(Suppl 1):94–102. https://doi.org/10.1111/jnc.12216.
Article CAS PubMed Google Scholar
Reetz K, Dogan I, Costa AS, Dafotakis M, Fedosov K, Giunti P, Parkinson MH, Sweeney MG, Mariotti C, Panzeri M, et al. Biological and clinical characteristics of the European Friedreich’s Ataxia Consortium for Translational studies (EFACTS) Cohort: a cross-sectional analysis of Baseline Data. Lancet Neurol. 2015;14:174–82. https://doi.org/10.1016/s1474-4422(14)70321-7.
Cook A, Giunti P. Friedreich’s Ataxia: clinical features, Pathogenesis and management. Br Med Bull. 2017;124:19–30. https://doi.org/10.1093/bmb/ldx034.
Article CAS PubMed PubMed Central Google Scholar
Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich’s Ataxia: classical and atypical phenotypes. J Neurochem. 2013;126:103–17. https://doi.org/10.1111/jnc.12317.
Article CAS PubMed Google Scholar
Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, Boesch S, Nachbauer W, Mariotti C, Mathews KD, et al. Safety and Efficacy of Omaveloxolone in Friedreich Ataxia (MOXIe study). Ann Neurol. 2021;89:212–25. https://doi.org/10.1002/ana.25934.
Article CAS PubMed Google Scholar
Lee A, Omaveloxolone. First Approval Drugs. 2023;83:725–9. https://doi.org/10.1007/s40265-023-01874-9.
Article CAS PubMed Google Scholar
Benini M, Fortuni S, Condò I, Alfedi G, Malisan F, Toschi N, Serio D, Massaro DS, Arcuri G, Testi R, et al. E3 ligase RNF126 directly ubiquitinates Frataxin, promoting its degradation: identification of a potential therapeutic target for Friedreich Ataxia. Cell Rep. 2017;18:2007–17. https://doi.org/10.1016/j.celrep.2017.01.079.
Article CAS PubMed PubMed Central Google Scholar
Alfedi G, Luffarelli R, Condò I, Pedini G, Mannucci L, Massaro DS, Benini M, Toschi N, Alaimo G, Panarello L, et al. Drug repositioning screening identifies Etravirine as a potential therapeutic for Friedreich’s Ataxia. Mov Disord. 2019;34:323–34. https://doi.org/10.1002/mds.27604.
Article CAS PubMed Google Scholar
Sivakumar A, Cherqui S. Advantages and limitations of Gene Therapy and Gene Editing for Friedreich’s Ataxia. Front Genome Ed. 2022;4:903139. https://doi.org/10.3389/fgeed.2022.903139.
Article PubMed PubMed Central Google Scholar
Keita M, McIntyre K, Rodden LN, Schadt K, Lynch DR. Friedreich Ataxia: clinical features and New Developments. Neurodegener Dis Manag. 2022;12:267–83. https://doi.org/10.2217/nmt-2022-0011.
Article CAS PubMed PubMed Central Google Scholar
Rufini A, Malisan F, Condò I, Testi R. Drug repositioning in Friedreich Ataxia. Front Neurosci. 2022;16. https://doi.org/10.3389/fnins.2022.814445.
Subramony SH. Degenerative ataxias: challenges in Clinical Research. Ann Clin Transl Neurol. 2016;4:53–60. https://doi.org/10.1002/acn3.374.
Article PubMed PubMed Central Google Scholar
Rizzacasa B, Amati F, Romeo F, Novelli G, Mehta JL. Epigenetic modification in coronary atherosclerosis: JACC Review topic of the Week. J Am Coll Cardiol. 2019;74:1352–65. https://doi.org/10.1016/j.jacc.2019.07.043.
Article CAS PubMed Google Scholar
Ma J. The development of epigenetics in the study of Disease Pathogenesis. Adv Exp Med Biol. 2020;1253. https://doi.org/10.1007/978-981-15-3449-2_2.
Rizzacasa B, Morini E, Mango R, Vancheri C, Budassi S, Massaro G, Maletta S, Macrini M, D’Annibale S, Romeo F, et al. MiR-423 is differentially expressed in patients with stable and unstable coronary artery disease: a pilot study. PLoS ONE. 2019;14:e0216363. https://doi.org/10.1371/journal.pone.0216363.
Article PubMed PubMed Central Google Scholar
Vancheri C, Morini E, Prandi FR, Barillà F, Romeo F, Novelli G, Amati F. Downregulation of circulating hsa-miR-200c-3p correlates with Dyslipidemia in patients with stable coronary artery disease. Int J Mol Sci. 2023;24:1112. https://doi.org/10.3390/ijms24021112.
Article CAS PubMed PubMed Central Google Scholar
Latini A, Vancheri C, Amati F, Morini E, Grelli S, Matteucci C, Petrone V, Colona VL, Murdocca M, Andreoni M, et al. Expression analysis of miRNA Hsa-Let7b-5p in Naso-Oropharyngeal swabs of COVID-19 patients supports its role in regulating ACE2 and DPP4 receptors. J Cell Mol Med. 2022;26:4940–8. https://doi.org/10.1111/jcmm.17492.
Article CAS PubMed PubMed Central Google Scholar
Ha T-Y. MicroRNAs in Human diseases: from Cancer to Cardiovascular Disease. Immune Netw. 2011;11:135–54. https://doi.org/10.4110/in.2011.11.3.135.
Article PubMed PubMed Central Google Scholar
Viswambharan V, Thanseem I, Vasu MM, Poovathinal SA, Anitha A. miRNAs as biomarkers of neurodegenerative disorders. Biomark Med. 2017;11:151–67. https://doi.org/10.2217/bmm-2016-0242.
Article CAS PubMed Google Scholar
Schließer P, Struebing FL, Northoff BH, Kurz A, Rémi J, Holdt L, Höglinger GU, Herms J, Koeglsperger T. Detection of a Parkinson’s Disease-Specific MicroRNA signature in nasal and oral swabs. Mov Disord. 2023. https://doi.org/10.1002/mds.29515.
Gomes BC, Peixinho N, Pisco R, Gromicho M, Pronto-Laborinho AC, Rueff J, de Carvalho M, Rodrigues AS. Differential expression of miRNAs in amyotrophic lateral sclerosis patients. Mol Neurobiol. 2023. https://doi.org/10.1007/s12035-023-03520-7.
Article PubMed PubMed Central Google Scholar
Li S, Lei Z, Sun T. The role of microRNAs in neurodegenerative diseases: a review. Cell Biol Toxicol. 2023;39:53–83. https://doi.org/10.1007/s10565-022-09761-x.
Article CAS PubMed Google Scholar
Bandiera S, Cartault F, Jannot A-S, Hatem E, Girard M, Rifai L, Loiseau C, Munnich A, Lyonnet S, Henrion-Caude A. Genetic variations creating microRNA Target sites in the FXN 3’-UTR affect Frataxin expression in Friedreich Ataxia. PLoS ONE. 2013;8:e54791. https://doi.org/10.1371/journal.pone.0054791.
Article CAS PubMed PubMed Central Google Scholar
Mahishi LH, Hart RP, Lynch DR, Ratan RR. Mir-886-3p levels are elevated in Friedreich Ataxia. J Neurosci. 2012;32:9369–73. https://doi.org/10.1523/JNEUROSCI.0059-12.2012.
Comments (0)